Human Immune Responses to Yellow Fever Vaccination (NCT00694655) | Clinical Trial Compass
CompletedPhase 4
Human Immune Responses to Yellow Fever Vaccination
United States239 participantsStarted 2008-05
Plain-language summary
The goal of this study is to use the live attenuated Yellow Fever Vaccine (YFV) as a safe and effective model for viral infection to understand human immune response to viral antigens. Study participants will receive the yellow fever vaccine and participation in the study may be as short as one month or as long as one year, depending on immune responses.
Who can participate
Age range18 Years – 45 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Able to understand and give informed consent
✓. Age 18-45 years
✓. Participant agrees not to take any live vaccines 30 days before or after (14 days for inactivated, including coronavirus disease 2019 (COVID-19) vaccination) yellow fever vaccination
✓. Women of child bearing potential must agree to use effective birth control throughout the duration of the study. A negative urine pregnancy test must be documented prior to vaccination. Participants who have a history of surgical sterilization or post-menopausal status \>1 year, are not required to have a pregnancy test.
Exclusion criteria
✕. Prior receipt of a yellow fever vaccine
✕. Lived in a country/area which is endemic for yellow fever
✕. Travel to country/area which is endemic for yellow fever. Subject to investigator discretion
✕. History of previous yellow fever, West Nile, Dengue, St. Louis encephalitis, Japanese encephalitis vaccination or infection
✕. Any history of allergy to eggs, chicken or gelatin or to any previous vaccine
✕. A history of a medical condition resulting in impaired immunity (such as HIV infection, cancer, particularly leukemia, lymphoma, use of immunosuppressive or antineoplastic drugs or X-ray treatment). Persons with previous skin cancers or cured non-lymphatic tumors are not excluded from the study
✕
What they're measuring
1
Magnitude of Yellow Fever Virus (YFV) specific T Cell Responses
Timeframe: Day 0 (day of vaccination), Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
2
Quality of YFV-specific T Cell Responses
Timeframe: Day 14, Day 21, Day 28, Day 90, Day 180, Day 360